Your browser doesn't support javascript.
Development of a PDRA Method for Detection of the D614G Mutation in COVID-19 Virus - Worldwide, 2021.
Chen, Ziwei; Shen, Xinxin; Wang, Ji; Zhao, Xiang; Gao, Yuan; Zhang, Ruiqin; Wang, Jinrong; Liu, Leping; Nie, Xinmin; Ma, Xuejun.
  • Chen Z; Department of Laboratory Medicine, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Shen X; Department of NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Wang J; Department of NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Zhao X; Department of NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Gao Y; Department of NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Zhang R; Department of NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Wang J; Department of NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Liu L; Department of NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Nie X; Department of Blood Transfusion, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Ma X; Department of Laboratory Medicine, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
China CDC Wkly ; 3(21): 448-453, 2021 May 21.
Article in English | MEDLINE | ID: covidwho-1237077
ABSTRACT

Background:

COVID-19 infection is a major public health problem worldwide, and the D614G mutation enhances the infectivity of COVID-19.

Methods:

A probe-directed recombinase amplification (PDRA) assay was discussed to detect the D614G mutation at 39 ℃ for 30 min. The sensitivity, specificity, and reproducibility of the PDRA were evaluated by D614 and G614 recombinant plasmids. The clinical performance of PDRA assay was validated by testing of 53 previously confirmed COVID-19 positive RNAs and 10 negative samples. Direct sequencing was carried out in parallel for comparison.

Result:

With good reproducibility and specificity, the PDRA assay worked well with the concentration in the range of 103-107 copies/reaction. Compared with direct sequencing as a reference, the recombinase-aided amplification (RAA) assay obtained 100% sensitivity and 100% specificity using clinical samples.

Conclusions:

A rapid, convenient, sensitive, and specific method to detect D614G mutation was developed, which offers a useful tool to monitor mutations in COVID-19 virus RNA.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Experimental Studies / Prognostic study Language: English Journal: China CDC Wkly Year: 2021 Document Type: Article Affiliation country: Ccdcw2021.115

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Experimental Studies / Prognostic study Language: English Journal: China CDC Wkly Year: 2021 Document Type: Article Affiliation country: Ccdcw2021.115